Morepen Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.5%1-day move

₹44.20

prior close

₹42.15

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1+0.0-0.2-0.6-2.5+4.8+3.0+2.5+1.9-3.6+15.6+23.8+28.1—

Up moveDown movePending

AI summary

Morepen Laboratories published its audited standalone and consolidated financial results for Q4 and the financial year ended 31st March 2026. The standalone Q4 showed total income of ₹4,307.12 Lakhs and net profit of ₹552.71 Lakhs (EPS ₹3.04). For the full year standalone, total income was ₹5,033.28 Lakhs and net profit ₹2,239.39 Lakhs (EPS ₹12.31), compared to ₹4,883.44 Lakhs and ₹1,814.58 Lakhs in the previous year. Consolidated full-year income stood at ₹5,122.68 Lakhs with net profit of ₹2,295.67 Lakhs (EPS ₹12.62). The results were approved by the Board on 26th May 2026 and published in newspapers on 27th May 2026 per SEBI listing regulations.

Likely market impact

Strong year-on-year profit growth with EPS rising from ₹9.97 to ₹12.31 on standalone basis. Positive signal for shareholders indicating improving financial performance.